Sarepta Therapeutics, Inc. SRPT
We take great care to ensure that the data presented and summarized in this overview for Sarepta Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SRPT
View all-
Black Rock Inc. New York, NY10.3MShares$826 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$727 Million0.02% of portfolio
-
Capital International Investors Los Angeles, CA8.7MShares$696 Million0.21% of portfolio
-
Janus Henderson Group PLC London, X04.33MShares$346 Million0.28% of portfolio
-
State Street Corp Boston, MA4.07MShares$325 Million0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA2.87MShares$229 Million1.85% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.56MShares$204 Million4.53% of portfolio
-
Wellington Management Group LLP Boston, MA2.07MShares$165 Million0.05% of portfolio
-
Jpmorgan Chase & CO New York, NY2.02MShares$162 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.96MShares$156 Million0.15% of portfolio
Latest Institutional Activity in SRPT
Top Purchases
Top Sells
About SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at SRPT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 12
2025
|
Claude Nicaise |
SELL
Open market or private sale
|
Direct |
2,491
-8.22%
|
$246,609
$99.64 P/Share
|
Mar 12
2025
|
Claude Nicaise |
BUY
Exercise of conversion of derivative security
|
Direct |
9,746
+24.34%
|
$243,650
$25.18 P/Share
|
Mar 10
2025
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+1.22%
|
-
|
Mar 10
2025
|
Claude Nicaise |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+10.39%
|
-
|
Mar 10
2025
|
Richard Barry |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+0.08%
|
-
|
Mar 10
2025
|
Louise Rodino Klapac Head of R&D, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
8,276
+8.91%
|
-
|
Mar 10
2025
|
Louise Rodino Klapac Head of R&D, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,463
-2.19%
|
$346,300
$100.13 P/Share
|
Mar 10
2025
|
Dallan Murray Chief Customer Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,276
+17.81%
|
-
|
Mar 10
2025
|
Dallan Murray Chief Customer Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,733
-5.67%
|
$373,300
$100.13 P/Share
|
Mar 10
2025
|
Bilal Arif Chief Tech Ops Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,276
+20.3%
|
-
|
Mar 10
2025
|
Bilal Arif Chief Tech Ops Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
523
-2.11%
|
$52,300
$100.13 P/Share
|
Mar 10
2025
|
Stephen Mayo |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+20.93%
|
-
|
Mar 10
2025
|
Hans Lennart Rudolf Wigzell |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+8.63%
|
-
|
Mar 10
2025
|
Ian Michael Estepan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,276
+11.67%
|
-
|
Mar 10
2025
|
Ian Michael Estepan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,941
-3.43%
|
$394,100
$100.13 P/Share
|
Mar 10
2025
|
Cristin Rothfuss EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
8,276
+28.16%
|
-
|
Mar 10
2025
|
Cristin Rothfuss EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
491
-3.68%
|
$49,100
$100.13 P/Share
|
Mar 10
2025
|
Michael Andrew Chambers |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+18.27%
|
-
|
Mar 10
2025
|
Kathryn Jean Boor |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+22.38%
|
-
|
Mar 10
2025
|
Deirdre P Connelly |
BUY
Grant, award, or other acquisition
|
Direct |
2,383
+31.32%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 65.3K shares |
---|---|
Exercise of conversion of derivative security | 192K shares |
Open market or private purchase | 37K shares |
Bona fide gift | 996 shares |
---|---|
Open market or private sale | 75K shares |
Payment of exercise price or tax liability | 77.9K shares |